榕樹生物標記了保健(POC)的血液測試來診斷創傷性腦損傷(TBI)。榕樹生物標誌物的研究已經確定了獨特的生物標記出現在病人的血液後的腦損傷。這些生物標誌物的檢測和量化可以提供早期跡象的腦外傷的早期幹預和管理。

Indena是一家致力於識別、開發和生產的活動原則來源於植物,用於製藥、保健食品和化妝品行業。Indena、民營意大利公司約有700名員工,其中包括10%致力於全職研究,旨在培養管理,製造、分銷業務在全世界40多個國家。Indena成功的關鍵是它的研究,包括:藥用植物的藥理篩選的好處;識別新的活躍的原則;提取和純化係統的開發和工業應用的前沿。phyto-chemical研究進行Indena Settala自己的研究中心,意大利。Indena同樣也與世界上最著名的大學和私人研究機構在生物的安全性和有效性臨床評估階段i的主要戰略目標之一的醫藥研究開發新的積極的原則的應用程序。這也是一個不可缺少的保健食品和化妝品行業的基礎。在製藥行業Indena目前專注於抗癌治療的發展,紫杉醇的成功後,以及在抗菌和抗病毒藥物。還在研究是活躍的原則治療病態和中樞神經係統功能障礙,如抑鬱,焦慮,陽痿,睡眠障礙、感覺過敏。 Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Stemina細胞發現發現和驗證小分子生物標誌物的高通量藥物篩選和疾病診斷使用一個人類所有係統由幹細胞和公司的代謝組學平台。代謝組學的目的是使小分子的發現可以作為候選人疾病生物標誌物和藥理功效和毒性。人類胚胎幹細胞的生物標記物預測代謝物是一個來源的候選人,診斷或衡量疾病或不良反應的進展。Stemina旨在提供化合物篩選和診斷發展製藥和生物技術行業和學術界根據合同服務或者聯合發現協議。

Cylene藥品臨床分期,私人公司開發小分子藥物對癌症新驗證目標。Cylene立場first-in-class抗癌藥物的發現和開發,激活p53腫瘤抑製和目標CK2蛋白激酶的藥物。公司的p53激活/波爾我計劃交付cx - 5461,第一階段階段小分子激活p53殺死癌細胞但不正常的。針對波爾我提供了第一個路徑選擇性地激活p53在惡性但不正常,健康的細胞。同樣,利用Cylene領導層CK2-dependent通路使first-in-class的創建,第二階段準備cx - 4945代理和cx - 8184,第二代代理,可以作為藥物的選擇合理的藥物組合對許多癌症跡象改善治療結果。Cylene提供代理的方法,使製藥公司擴大投資組合和擴展功效,生命周期,達到目前的癌症療法。

ReproCell是幹細胞技術的開發人員。公司開發各種產品,一個潛在的主題,致力於幹細胞技術,解決研究者和臨床醫生的需求。產品範圍包括試劑ES / iPS細胞和幹細胞的功能細胞。

眼睛創新科學develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform features a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized in the United States, Europe, India, China and Mexico for the treatment of infected wounds. The solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America.